Viking Therapeutics, Inc. (VKTX)

業務介紹

維京治療公司是一家處於臨床階段的生物製藥公司,專注於開發治療代謝和內分泌失調的新型療法。該公司的主要藥物候選物是VK2809,這是一種口服可用的組織和受體亞型選擇性的甲狀腺素受體β(TRβ)激動劑,正處於II期b期臨床試驗階段,用於治療經活檢確診的非酒精性脂肪肝炎以及非酒精性脂肪肝。該公司還開發了VK5211,這是一種口服可用的非類固醇選擇性雄激素受體調節劑,正處於II期臨床試驗階段,用於治療從非選擇性髖部骨折手術中恢復的患者;VK0612,這是一種口服可用的II期b期就緒的II型糖尿病藥物候選物;以及VK0214,這是一種口服可用的組織和受體亞型選擇性的TRβ激動劑,用於治療X連鎖型腦白質營養不良。該公司成立於2012年,總部位於加利福尼亞州聖地亞哥。



Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

公司網址

https://www.vikingtherapeutics.com